Primary Objectives
1. To determine whether high-dose chemotherapy (HDCT) with purged autologous stem cell products will reduce the presence of circulating tumor cells (CTCs) among metastatic breast cancer (MBC) patients after receiving high-dose chemotherapy autologous hematopoietic stem cell transplantation.
2. To determine whether reduction of CTCs will correlate with prolonged progression-free survival (PFS).
Secondary Objectives:
1. To determine whether reduction of CTCs will correlate with prolonged overall survival (OS).
2. To characterize the biology of CTC. |